| Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial AK Davis, FS Barrett, DG May, MP Cosimano, ND Sepeda, MW Johnson, ... JAMA psychiatry 78 (5), 481-489, 2021 | 1206 | 2021 |
| Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety AK Davis, FS Barrett, RR Griffiths Journal of contextual behavioral science 15, 39-45, 2020 | 349 | 2020 |
| Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up N Gukasyan, AK Davis, FS Barrett, MP Cosimano, ND Sepeda, ... Journal of Psychopharmacology 36 (2), 151-158, 2022 | 345 | 2022 |
| Survey of subjective" God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca … RR Griffiths, ES Hurwitz, AK Davis, MW Johnson, R Jesse PloS one 14 (4), e0214377, 2019 | 269 | 2019 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use A Garcia-Romeu, AK Davis, F Erowid, E Erowid, RR Griffiths, ... Journal of Psychopharmacology 33 (9), 1088-1101, 2019 | 261 | 2019 |
| Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder MK Doss, M Považan, MD Rosenberg, ND Sepeda, AK Davis, PH Finan, ... Translational psychiatry 11 (1), 574, 2021 | 250 | 2021 |
| Long-term effects of psychedelic drugs: A systematic review JS Aday, CM Mitzkovitz, EK Bloesch, CC Davoli, AK Davis Neuroscience & Biobehavioral Reviews 113, 179-189, 2020 | 249 | 2020 |
| A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy JB Luoma, C Chwyl, GJ Bathje, AK Davis, R Lancelotta Journal of Psychoactive Drugs 52 (4), 289-299, 2020 | 208 | 2020 |
| Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects JS Aday, AK Davis, CM Mitzkovitz, EK Bloesch, CC Davoli ACS Pharmacology & Translational Science 4 (2), 424-435, 2021 | 174 | 2021 |
| Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects AK Davis, JM Clifton, EG Weaver, ES Hurwitz, MW Johnson, RR Griffiths Journal of Psychopharmacology 34 (9), 1008-1020, 2020 | 166 | 2020 |
| The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption AK Davis, JP Barsuglia, R Lancelotta, RM Grant, E Renn Journal of Psychopharmacology 32 (7), 779-792, 2018 | 158 | 2018 |
| 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety AK Davis, S So, R Lancelotta, JP Barsuglia, RR Griffiths The American journal of drug and alcohol abuse 45 (2), 161-169, 2019 | 151 | 2019 |
| Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey A Garcia-Romeu, AK Davis, E Erowid, F Erowid, RR Griffiths, ... Frontiers in psychiatry 10, 955, 2020 | 134 | 2020 |
| People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences MT Williams, AK Davis, Y Xin, ND Sepeda, PC Grigas, S Sinnott, ... Drugs: Education, Prevention and Policy 28 (3), 215-226, 2021 | 126 | 2021 |
| Acceptance of non-abstinence goals by addiction professionals in the United States. AK Davis, H Rosenberg Psychology of Addictive Behaviors 27 (4), 1102, 2013 | 124 | 2013 |
| Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD AK Davis, FS Barrett, S So, N Gukasyan, TC Swift, RR Griffiths Journal of Psychopharmacology 35 (4), 437-446, 2021 | 114 | 2021 |
| Prospective examination of synthetic 5-methoxy-N, N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment MV Uthaug, R Lancelotta, A Szabo, AK Davis, J Riba, JG Ramaekers Psychopharmacology 237, 773-785, 2020 | 102 | 2020 |
| Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study J Barsuglia, AK Davis, R Palmer, R Lancelotta, AM Windham-Herman, ... Frontiers in psychology 9, 2459, 2018 | 87 | 2018 |
| Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States AK Davis, G Agin-Liebes, M España, B Pilecki, J Luoma Journal of psychoactive drugs 54 (4), 309-318, 2022 | 86 | 2022 |
| The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N, N‐dimethyltryptamine (5‐MeO‐DMT) JT Reckweg, MV Uthaug, A Szabo, AK Davis, R Lancelotta, NL Mason, ... Journal of Neurochemistry 162 (1), 128-146, 2022 | 79 | 2022 |
Roland R. GriffithsProfessor, Departments of Psychiatry and Neuroscience, Johns Hopkins University School of MedicineПодтвержден адрес электронной почты в домене jhmi.edu